Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$891M |
| 2 |
Union Pacific
UNP
|
+$622M |
| 3 |
Salesforce
CRM
|
+$418M |
| 4 |
Edwards Lifesciences
EW
|
+$405M |
| 5 |
lululemon athletica
LULU
|
+$347M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Caterpillar
CAT
|
+$680M |
| 2 |
Texas Instruments
TXN
|
+$585M |
| 3 |
RHT
Red Hat Inc
RHT
|
+$571M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$558M |
| 5 |
Parker-Hannifin
PH
|
+$556M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.09% |
| 2 | Healthcare | 17.49% |
| 3 | Consumer Discretionary | 17.05% |
| 4 | Financials | 12.69% |
| 5 | Communication Services | 11.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Celanese
CE
$4.81B
| $5.62M | 0.01% |
62,509
-357,445
| -85% | -$35M |
|
|
ICD
477
DELISTED
Independence Contract Drilling, Inc.
ICD
| $5.57M | 0.01% |
89,278
+1,346
| +2% | +$101K |
|
|
FSTX
478
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $5.5M | 0.01% |
132,342
-37,991
| -22% | -$1.71M |
|
479
Quanterix
QTRX
$175M
| $5.45M | 0.01% |
297,563
+3,249
| +1% | +$58.3K |
|
|
RDC
480
DELISTED
Rowan Companies Plc
RDC
| $5.33M | 0.01% |
635,317
-122,476
| -16% | -$1.8M |
|
|
IMGN
481
DELISTED
Immunogen Inc
IMGN
| $5.15M | 0.01% |
1,072,821
-100,539
| -9% | -$610K |
|
|
WCN
482
Waste Connections
WCN
$42.3B
| $5.12M | 0.01% |
68,959
-2,088
| -3% | -$159K |
|
|
EQGP
483
DELISTED
EQGP Holdings, LP
EQGP
| $5.08M | 0.01% |
254,453
-11,921
| -4% | -$221K |
|
|
SAGE
484
CALL
DELISTED
Sage Therapeutics
SAGE
| $4.79M | 0.01% |
+50,000
| New | +$5.72M |
|
485
Viking Therapeutics
VKTX
$3.8B
| $4.75M | 0.01% |
620,789
+75,389
| +14% | +$901K |
|
|
IPHI
486
DELISTED
INPHI CORPORATION
IPHI
| $4.53M | 0.01% |
+140,900
| New | +$4.89M |
|
487
Mueller Water Products
MWA
$4.04B
| $4.46M | 0.01% |
490,150
+401,018
| +450% | +$4.2M |
|
488
Select Water Solutions
WTTR
$2.29B
| $4.37M | ﹤0.01% |
690,620
-47,952
| -6% | -$474K |
|
|
ENLC
489
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
| $4.16M | ﹤0.01% |
437,940
-20,514
| -4% | -$264K |
|
490
Vanguard Morningstar Growth ETF
VUG
$225B
| $3.83M | ﹤0.01% |
+171,198
| New | +$4.15M |
|
491
Walt Disney
DIS
$170B
| $3.7M | ﹤0.01% |
33,744
-3,991
| -11% | -$454K |
|
|
AUTL
492
Autolus Therapeutics
AUTL
$484M
| $3.51M | ﹤0.01% |
106,971
-12,219
| -10% | -$402K |
|
493
Antero Midstream
AM
$10.4B
| $3.49M | ﹤0.01% |
312,517
-14,638
| -4% | -$223K |
|
|
DBVT
494
DBV Technologies
DBVT
$804M
| $3.44M | ﹤0.01% |
53,571
-119,558
| -69% | -$19.2M |
|
495
Inspire Medical Systems
INSP
$1.5B
| $3.17M | ﹤0.01% |
75,081
-14,899
| -17% | -$633K |
|
496
RenaissanceRe
RNR
$13.4B
| $3.16M | ﹤0.01% |
23,659
| – | – |
|
497
Fate Therapeutics
FATE
$291M
| $3M | ﹤0.01% |
233,504
-66,496
| -22% | -$927K |
|
498
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
$26.7B
| $2.36M | ﹤0.01% |
+7,792
| New | +$2.59M |
|
|
SBT
499
DELISTED
Sterling Bancorp, Inc. Common Stock
SBT
| $2.27M | ﹤0.01% |
326,471
+41,502
| +15% | +$390K |
|
500
Micron Technology
MU
$937B
| $2.13M | ﹤0.01% |
67,277
+32,574
| +94% | +$1.23M |
|
Similar funds
Jennison Associates's Q4 2018 Portfolio in Review
As of Q4 2018, Jennison Associates held 753 positions worth $89.4B, down 18% from $109B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Jennison Associates's Q4 2018 filing shows 95 new, 255 increased, 283 reduced and 113 closed positions. Its largest new stake was lululemon athletica: 2,588,881 shares worth $315M. The largest sale was Caterpillar, an estimated $680M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 22% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Jennison Associates's largest Q4 2018 buy was lululemon athletica: 2,588,881 shares worth $315M.
- Jennison Associates added most to Merck in Q4 2018, an estimated $891M increase.
- Jennison Associates's biggest Q4 2018 reduction was Caterpillar, cutting an estimated $680M.
- Jennison Associates fully exited Tiffany & Co. in Q4 2018, selling an estimated $151M.
- Jennison Associates's ten largest holdings make up 30% of its $89.4B portfolio in Q4 2018.
- Jennison Associates opened 95 new positions and closed 113 in Q4 2018.
- Jennison Associates's portfolio value fell 18% quarter-over-quarter to $89.4B.
Based on Jennison Associates's 13F filing for Q4 2018, filed 6 Feb 2019.